Biodesix has filed a patent for a method of predicting the prognosis of patients with myelodysplastic syndrome (MDS). The method involves using mass-spectrometry data obtained from a blood-based sample and a computer classifier to assign a classification label of either “Early” or “Late” to the patient’s sample. Patients classified as “Early” are predicted to have a poor prognosis, while those classified as “Late” are predicted to have a better prognosis and longer survival time. The method has shown significant independent prognostic power, complementing existing prognostic factors. GlobalData’s report on Biodesix gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Biodesix, AI-assisted drug screening was a key innovation area identified from patents. Biodesix's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Method for predicting prognosis of mds patients using mass spectrometry
A recently filed patent (Publication Number: US20230197426A1) describes a method for predicting the prognosis of patients with myelodysplastic syndrome (MDS). The method involves performing MALDI-TOF mass spectrometry on a blood-based sample obtained from the MDS patient, acquiring mass spectral data, and obtaining integrated intensity values of pre-determined mass-spectral features. These integrated intensity values are then processed by a programmed computer implementing a classifier. The classifier compares the integrated intensity values with feature values from a training set of class-labeled mass spectral data obtained from other MDS patients and generates a class label associated with the prognosis of the MDS patient.
The patent also describes a classifier for predicting the prognosis of MDS patients. The classifier includes a memory storing a reference set of mass spectral data obtained from blood-based samples of multiple MDS patients and a programmed computer configured to implement a classifier as a combination of filtered mini-classifiers with drop-out regularization. The reference set of mass spectral data includes feature values of specific mass-to-charge ratio (m/z) features listed in Appendix A.
Additionally, the patent describes a laboratory testing system for conducting tests on blood-based samples from MDS patients and predicting their prognosis. The system includes a MALDI-TOF mass spectrometer for conducting mass spectrometry on the blood-based sample, a memory storing a reference set of mass spectral data obtained from multiple MDS patients, and a programmed computer implementing a classifier. The programmed computer generates a class label for the sample based on the reference set and the resulting mass spectral data, which is associated with the prognosis of the MDS patient.
Overall, this patent presents a method, classifier, and laboratory testing system for predicting the prognosis of MDS patients using MALDI-TOF mass spectrometry and integrated intensity values of specific mass-spectral features. By comparing the patient's data with a training set, the classifier can generate a class label associated with the patient's prognosis. This technology has the potential to improve the accuracy and efficiency of prognosis prediction for MDS patients, aiding in personalized treatment decisions.
To know more about GlobalData’s detailed insights on Biodesix, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
